Lifeward Ltd. reported revenue of $6.2 million for the third quarter of 2025, up 1.0% from $6.1 million in the third quarter of 2024 and an 8.0% increase from $5.7 million in the second quarter of 2025. Revenue from the sale of traditional products and services, including ReWalk Personal exoskeletons and the MyoCycle FES bike, was $3.1 million, representing a 24.0% increase year-over-year, attributed to higher Medicare-related sales. The company recorded a net loss of $3.6 million, or $0.41 per share, compared to a net loss of $4.0 million, or $0.45 per share, in the same period last year. Cash used in operations decreased by 16.0% to $3.8 million from $4.5 million in the prior year quarter. As of September 30, 2025, Lifeward had $2.0 million in unrestricted cash and no debt. After the quarter ended, Lifeward entered into a $3.0 million loan agreement with Oramed Ltd. The company reaffirmed its full-year 2025 revenue guidance of $24 to $26 million and projected a non-GAAP net loss between $12 and $14 million. The quarter marked a record for Medicare beneficiary placements following the formalization of the Medicare fee schedule in April 2024.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lifeward Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001178913-25-003837), on November 14, 2025, and is solely responsible for the information contained therein.
Comments